Ro vs Sprout Health
Two GLP-1 desks, one scoreboard. We put Ro and Sprout Health head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 86 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make Sprout Health a bad call — it's best for patients who want a low compounded entry price but the option of brand-name wegovy or zepbound on the same account, with minimal onboarding. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Ro | Sprout Health | |
|---|---|---|
| Brief Score | 87/100 (B+) | 86/100 (B) |
| Semaglutide | Not disclosed | $149/mo |
| Tirzepatide | Not disclosed | $199/mo |
| Coverage | Multi-state | Not disclosed |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.